Results
The pharmacokinetics (PK) of iberdomide were adequately described with a
two-compartment model with first-order absorption and elimination. A
first order conversion rate was used to link the one-compartment linear
elimination metabolite model with the parent model. Subject type
(multiple myeloma subjects vs. healthy subject) was a statistically
significant covariate on apparent clearance (CL/F) and apparent volume
of distribution for the central compartment (V1/F), suggesting different
PK between subjects with multiple myeloma and healthy subjects.
Aspartate aminotransferase (AST), alkaline phosphatase (ALP) and sex
were statistically but not clinically relevant covariates on CL/F.
Metabolite (M12) PK tracked the PK of iberdomide. The metabolite to
parent ratio was consistent across doses and combinations.